Akari Therapeutics, Plc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AKTX Nasdaq 2836 www.akaritx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Akari Therapeutics, Plc

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala - Apr 22nd, 2025 1:05 pm
Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update - Apr 16th, 2025 12:00 pm
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer - Mar 20th, 2025 12:35 pm
Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules - Mar 3rd, 2025 2:00 pm
Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - Feb 19th, 2025 2:00 pm
Akari Therapeutics Joins Webull Corporate Connect Service Platform - Feb 3rd, 2025 1:00 pm
Akari Therapeutics Announces Key Leadership Appointments - Dec 18th, 2024 1:51 pm
Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer - Dec 16th, 2024 2:05 pm
Akari Therapeutics Regains Full Nasdaq Compliance - Nov 19th, 2024 1:00 pm
This Akari Therapeutics Insider Increased Their Holding By 69% Last Year - Nov 15th, 2024 1:39 pm
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio - Nov 14th, 2024 9:15 pm
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger - Nov 8th, 2024 1:00 pm
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger - Oct 15th, 2024 12:00 pm
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics - Sep 17th, 2024 12:00 pm
Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights - Aug 19th, 2024 8:15 pm
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy - Aug 19th, 2024 12:00 pm
Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders - Jun 5th, 2024 12:00 pm
Akari Therapeutics Secures $7.6 Million in Upsized Financing Round - Jun 4th, 2024 12:00 pm
Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights - May 16th, 2024 12:00 pm
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics - May 1st, 2024 12:01 pm